UNSPSC 51111755: Nogalamycin

This classification denotes an anthracycline antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L059DCD6IP. European Medicines Agency schedules Nogalamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09341MIG. Nogalamycin generally arises in the molecular formula C39H49NO16.

The term NOGALAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) NOGALAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nogalamycin under HS 29419000 and SITC 54139. As of Q4 2014, NOGALAMYCIN remains the US FDA Preferred Term for this commodity. Nogalamycin bears US NLM identifiers UMLS ID C0028261 and NCI Concept Code C700.

UNSPSC 51111755 Nogalamycin is a Commodity code nominally identifying a single pharmaceutical product, yet state and local recent solicitation activity under this code shows little relevance to the code's specific scope. Recent opportunities tagged to this code reflect broader pharmaceutical procurement and emergency medical supply acquisition rather than nogalamycin itself. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, with delivery to the Seminole County Community Health Building on a quarterly schedule; the City of Tampa's Purchasing Department released ITB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, including respiratory equipment, cardiac monitoring electrodes, endotracheal tubes, and oxygen delivery systems, with a $700,000 estimated contract value and small local business enterprise (SLBE) sheltered-market designation offering a 5 percent bid discount. These solicitations reflect emergency response and community health supply sourcing rather than a single active pharmaceutical ingredient or chemotherapy agent. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 in January 2026 to establish multiple vendor contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities, including Oregon, requiring all products available by May 15, 2026, with proposals due March 26, 2026.

Activity under this code spans county health departments, municipal fire and rescue divisions, and state cooperative purchasing consortiums across Florida, Texas, and Minnesota. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 as preliminary market intelligence on direct-to-manufacturer prescription fulfillment to inform future procurement strategy, reflecting upstream contracting exploration rather than end-product procurement. The geographic spread evident in recent opportunities includes the Southeast (Florida), South (Texas, Minnesota cooperative), and multi-state cooperative purchasing. The code shows material recent solicitation activity, yet the mismatch between nogalamycin as a specific pharmaceutical product and the actual procurement scope—naloxone, generic multi-source pharmaceuticals, emergency medical supplies, and OTC products—indicates that issuers are applying this commodity code broadly to pharmaceutical and medical supply acquisitions without precise alignment to the code's nominal definition.